Author: Peter Mansell

£20 million for UK Centres of Excellence in public health research

A coalition of funders has awarded a total of £20 million (€26.8 million) under the umbrella of the UK Clinical Research Collaboration (UKCRC) to five new Centres of Excellence, set up to conduct research on a broad range of public health issues such as health inequalities, obesity, exercise, smoking, alcohol and drugs.

Read More

Merck, Schering-Plough suspend Vytorin TV ads

Merck & Co and Schering-Plough have temporarily suspended television advertising for their combination cholesterol treatment Vytorin (ezetimibe + simvastatin) in the US, as Vytorin prescriptions and the companies’ share prices buckle under the fall-out from the now notorious ENHANCE trial.

Read More

New model needed for maternal health drugs

Only 17 drugs are in active development for maternal health indications, while only one new class of drugs for pregnant women has been licensed in the last 20 years, a study has found. Among the nine new chemical entities (NCEs) in preclinical or clinical development for maternal health, there are no new classes of drugs in clinical trials for primary obstetric applications.

Read More